Skip to Main Content

Paper Details

Fumarate hydratase variant prevalence and manifestations among individuals receiving germline testing.
Cancer
8
2022
AD HLRCC, AD HLRCC variants, AR FMRD, AR FMRD variants, FH, FH variants, FMRD, Fumarate, Fumarate hydratase variant, HLRCC, RCC, RESULTS FH, autosomal dominant (AD) hereditary leiomyomatosis, cancer, common cancer syndrome, fumarase, fumarase deficiency, fumarate, fumarate hydratase, renal cell cancer, renal cell carcinoma
Carcinoma, Renal Cell, Female, Fumarate Hydratase, Germ Cells, Germ-Line Mutation, Humans, Kidney Neoplasms, Leiomyomatosis, Neoplastic Syndromes, Hereditary, Prevalence, Skin Neoplasms, Uterine Neoplasms
Author NameAffiliation
Eric LuUniversity of California Los Angeles
Kathryn E Hatchell
Sarah M Nielsen
Edward D Esplin
Edward D Esplin
Karen Ouyang
Keith Nykamp
Shirin ZavoshiInstitute of Urologic Oncology, University of California Los Angeles
Shantao LiYale University
Liying ZhangUniversity of California Los Angeles
Liying ZhangJonsson Comprehensive Cancer Center, University of California Los Angeles
Blake R WildeUniversity of California Los Angeles
Heather R ChristofkJonsson Comprehensive Cancer Center, University of California Los Angeles
Heather R ChristofkUniversity of California Los Angeles
Paul C BoutrosInstitute of Urologic Oncology, University of California Los Angeles
Paul C BoutrosJonsson Comprehensive Cancer Center, University of California Los Angeles
Paul C BoutrosUniversity of California Los Angeles
Paul C BoutrosUniversity of California Los Angeles
Brian ShuchInstitute of Urologic Oncology, University of California Los Angeles
Brian ShuchJonsson Comprehensive Cancer Center, University of California Los Angeles
  • 1 - 20

Datasets

Release 1.2